Clinical outcomes with vutrisiran in transthyretin amyloidosis: A systematic review and meta-analysis of randomized trials
Global Cardiology Science and Practice · 29.06.2026 · 2026 (3)
DOI: 10.21542/gcsp.2026.25 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Global Cardiology Science and Practice, online erschienen am 29.06.2026. Verfasst von Faizan Ahmed und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Jersey Shore University Medical Centre, Hackensack Meridian Health, Neptune, NJ, USA. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Transthyretin amyloidosis (ATTR) is a progressive disease that causes a restrictive cardiomyopathy. Vutrisiran, a subcutaneous RNA interference (RNAi) therapy, is an approved treatment. This systematic review and meta-analysis evaluates its efficacy and safety with respect to transthyretin (TTR) reduction, functional capacity, quality of life, mortality, and adverse events.
Methods
We identified 1,032 records, of which three randomized controlled trials — HELIOS-A, HELIOS-B, and a Phase 1 study — comprising 976 participants (508 vutrisiran; 468 comparator) met the inclusion criteria. Comparator participants received placebo, patisiran (an active reference comparator in HELIOS-A), or external placebo from the APOLLO trial. Outcomes assessed were TTR reduction, functional capacity, quality of life, mortality, and adverse events, pooled using random-effects models reporting mean differences and risk ratios.
Results
Vutrisiran achieved a rapid, durable TTR reduction of up to 97% in healthy volunteers at the highest dose, and a sustained steady-state reduction in the HELIOS-A and HELIOS-B trials. QoL outcomes showed a protective effect of vutrisiran, with slowed deterioration in the intervention group. Functional outcomes (10-MWT, 6-MWT) suggested slower decline in mobility and functional capacity. Mortality showed a non-significant reduction (RR 0.51; p=0.29; I²=62%), with most deaths considered unrelated to treatment. The safety analysis showed fewer falls (RR 0.62; p=0.001; I²=0%) but no significant difference in overall adverse events (AEs) (RR 1.01; p=0.76) or serious AEs (RR 0.82; p=0.23). A sensitivity analysis supported the adverse-event findings.
Conclusions
Vutrisiran consistently suppressed TTR and showed signals of benefit in quality of life, function, and mortality, though most of these outcomes did not reach statistical significance. It reduced fall risk without increasing adverse events, indicating a favourable safety profile. Larger, long-term RCTs are needed to confirm survival and functional benefits.
Autor:innen und Institutionen
- Department of Medicine, Jersey Shore University Medical Centre, Hackensack Meridian Health, Neptune, NJ, USA.
- Allama Iqbal Medical College, Lahore, Pakistan.
- Dow University of Health and Sciences, Karachi, Pakistan.
- Jinnah Sindh Medical University, Karachi, Pakistan.
- Shaikh Khalifa Bin Zayed Al-Nahyan Medical and Dental College, Lahore, Pakistan.
- Department of Medicine, Fatima Jinnah Medical University, Lahore, Pakistan.
Zitieren
APA
Ahmed, F., Haider, F., Zulfiqar, A., Nihal, T., Khalid, M., Dar, A., Rauf, S., Saleem, N. U. A., Farooq, H., Tahir, H. B., Ali, R., Shah, H. H., Patel, S., Hossain, M., & Alenezi, F. (2026). Clinical outcomes with vutrisiran in transthyretin amyloidosis: A systematic review and meta-analysis of randomized trials. Global Cardiology Science and Practice, 2026(3). https://doi.org/10.21542/gcsp.2026.25
Vancouver
Ahmed F, Haider F, Zulfiqar A, Nihal T, Khalid M, Dar A, et al. Clinical outcomes with vutrisiran in transthyretin amyloidosis: A systematic review and meta-analysis of randomized trials. Global Cardiology Science and Practice. 2026;2026(3). doi:10.21542/gcsp.2026.25
BibTeX
@article{Ahmed2026,
author = {Ahmed, Faizan and Haider, Faseeh and Zulfiqar, Ayesha and Nihal, Tooba and Khalid, Maliha and Dar, Areej and Rauf, Saman and Saleem, Noor Ul Ain and Farooq, Hassan and Tahir, Haris Bin and Ali, Ramsha and Shah, Haider Hussain and Patel, Swapnil and Hossain, Mohammad and Alenezi, Fawaz},
title = {Clinical outcomes with vutrisiran in transthyretin amyloidosis: A systematic review and meta-analysis of randomized trials},
journal = {Global Cardiology Science and Practice},
year = {2026},
volume = {2026},
number = {3},
doi = {10.21542/gcsp.2026.25}
}
EUVIMED